CLINICAL TRIALS SUPPORT UNIT

临床试验支持单位

基本信息

  • 批准号:
    8181015
  • 负责人:
  • 金额:
    $ 17.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-17 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

The Clinical Trials Support Unit (CTSU) is a central resource for coordination and reporting on all cancer related clinical research within the College and its affiliated hospitals and ambulatory care centers. The CTSU facilitates liaison with investigators, cooperative groups, federal agencies, and the pharmaceutical industry. In the past 3 years, the CTSU has particularly focused on establishing clinical trials infrastructure for investigators and institutions with less prior experience and knowledge in this area in order to increase clinical trial enrollment to a wide spectrum of cancer-related studies. The CTSU has targeted hospitals and institutions with a higher proportion of minority and economically disadvantaged patients, providing greater access to participation in clinical research for these populations. The CTSU provides overall coordination of and reporting on cancer relevant clinical studies in the DLDCC via 4 major functions: 1) Assistance with regulatory and administrative matters relating to clinical research and trials, including IRB compliance and approval, ongoing amendments and renewal, external agency compliance (such as the FDA), maintenance of regulatory files, 2) Clinical trials informatics expertise especially maintaining an electronic database of cancer related clinical protocols, patient registry and clinical data, and monitoring and reporting on accrual, 3) Quality assurance auditing and personnel training and 4) Research nursing/clinical trials management especially for less experienced investigators or those with limited programs. The CTSU provides efficient, cost-effective support to aid Cancer Center investigators in the conduct of scientifically valuable cancer clinical trials and improves access to these trials, especially for underserved minorities. The main offices of the CTSU are in the Cancer Center administrative offices on the 4th floor of the Cullen Bldg at Baylor College of Medicine with CCGT and Pediatric CTSU offices in the Feigin Center. On site offices for Research Nurses/Coordinators are located in each of the College's major affiliated clinical facilities including the Baylor Clinic, Texas Children's Hospital, the Methodist Hospital (adult component of the CCGT program), the Ben Taub Hospital, and the Michael E. DeBakey VA Medical Center. The Resource Leader is Martha Mims, M.D., Ph.D.
临床试验支持单位(CTSU)是协调和报告学院及其附属医院和门诊护理中心内所有癌症相关临床研究的中心资源。CTSU促进与研究者、合作团体、联邦机构和制药行业的联络。在过去的3年里,CTSU特别关注为研究者和机构建立临床试验基础设施,这些研究者和机构在这一领域的经验和知识较少,以增加广泛的癌症相关研究的临床试验入组。CTSU针对医院和 少数民族和经济困难患者比例较高的机构,为这些人群提供更多参与临床研究的机会。 CTSU通过4个主要职能对DLDCC中的癌症相关临床研究进行总体协调和报告:1)协助与临床研究和试验相关的监管和行政事务,包括IRB合规和批准,正在进行的修订和更新,外部机构合规(如FDA),监管文件的维护,2)临床试验信息学专业知识,特别是维护癌症相关临床方案的电子数据库,患者登记和临床数据,监测和报告应计费用,3)质量保证稽查和人员培训,以及4) 研究护理/临床试验管理,特别是对于经验不足的研究者或项目有限的研究者。 CTSU提供有效的,具有成本效益的支持,以帮助癌症中心的研究人员在科学上有价值的癌症临床试验的进行,并改善这些试验的访问,特别是为服务不足的少数民族。CTSU的主要办公室位于贝勒医学院卡伦大楼4楼的癌症中心行政办公室,CCGT和儿科CTSU办公室位于费金中心。 研究护士/协调员的现场办公室位于学院的每个主要附属临床设施,包括贝勒诊所,得克萨斯州儿童医院,卫理公会医院(成人部分), CCGT计划)、本·陶布医院和迈克尔·E·。DeBakey VA医疗中心。 资源负责人是Martha Mims,医学博士,博士

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martha P. Mims其他文献

Paraneoplastic Nephrotic Syndrome and Inflammatory Arthritis at Diagnosis in Hodgkin Lymphoma
  • DOI:
    10.1016/j.clml.2012.09.006
  • 发表时间:
    2013-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Daniel B. Aruch;Martha P. Mims
  • 通讯作者:
    Martha P. Mims
Clinical Outcomes of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in a County Hospital System
  • DOI:
    10.1182/blood-2023-173927
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Jun Yang Jiang;Chijioke Nze;Danielle Guffey;Rockbum Kim;Abiodun O. Ouyomi;Omar Rosales;Raka Bandyo;Akiva Diamond;Gustavo A. Rivero;Courtney Nicole Miller-Chism;Mark M. Udden;Martha P. Mims;Christopher R. Flowers;Ang Li;Purnima Sravanti Teegavarapu
  • 通讯作者:
    Purnima Sravanti Teegavarapu
Disparities Among Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
  • DOI:
    10.1182/blood-2023-190913
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Elyse Lopez;Deepa Dongarwar;Martha P. Mims;Sara Taveras Alam
  • 通讯作者:
    Sara Taveras Alam
Real-World Validation of the European Leukemia Network 2022 Risk Stratification in Acute Myelogenous Leukemia
  • DOI:
    10.1182/blood-2023-189309
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah Elizabeth Mudra;Paul Sackstein;Lacey Scott Williams;Garrett Diltz;Rachel Zemel;Ashwin Kumar;Purnima Sravanti Teegavarapu;Martha P. Mims;Catherine Lai;Kimberley Doucette;Gustavo A. Rivero
  • 通讯作者:
    Gustavo A. Rivero
Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system
  • DOI:
    10.1016/j.bneo.2024.100020
  • 发表时间:
    2024-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jun Y. Jiang;Chijioke Nze;Danielle Guffey;Rockbum Kim;Abiodun O. Oluyomi;Omar Rosales;Raka Bandyo;Courtney N. Miller-Chism;Mark M. Udden;Martha P. Mims;Hilary Ma;Gustavo A. Rivero;Akiva Diamond;Purnima S. Teegavarapu;Ang Li;Christopher R. Flowers
  • 通讯作者:
    Christopher R. Flowers

Martha P. Mims的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martha P. Mims', 18)}}的其他基金

Clinical, Protocol and Data Management
临床、方案和数据管理
  • 批准号:
    10674569
  • 财政年份:
    2007
  • 资助金额:
    $ 17.81万
  • 项目类别:
Clinical Trials Support Unit
临床试验支持单位
  • 批准号:
    7514693
  • 财政年份:
    2007
  • 资助金额:
    $ 17.81万
  • 项目类别:
Clinical, Protocol and Data Management
临床、方案和数据管理
  • 批准号:
    10439832
  • 财政年份:
    2007
  • 资助金额:
    $ 17.81万
  • 项目类别:
DMT1:Tissue specific expression & alternative splicing
DMT1:组织特异性表达
  • 批准号:
    6858234
  • 财政年份:
    2005
  • 资助金额:
    $ 17.81万
  • 项目类别:
DMT1:Tissue specific expression & alternative splicing
DMT1:组织特异性表达
  • 批准号:
    7031607
  • 财政年份:
    2005
  • 资助金额:
    $ 17.81万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223250
  • 财政年份:
    1993
  • 资助金额:
    $ 17.81万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2392677
  • 财政年份:
    1993
  • 资助金额:
    $ 17.81万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223251
  • 财政年份:
    1993
  • 资助金额:
    $ 17.81万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223252
  • 财政年份:
    1993
  • 资助金额:
    $ 17.81万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    3366035
  • 财政年份:
    1993
  • 资助金额:
    $ 17.81万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 17.81万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 17.81万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 17.81万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 17.81万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
  • 批准号:
    03660315
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 17.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了